Objective: Astroblastoma is an unusual brain tumor in childhood. Tumor usually arises from cerebral hemispheres. This large tumor is well-demarcated, lobulated, solid or cystic, and therefore, may resemble glioblastoma. Histopathologically, there are two types of astroblastoma: well-differentiated (low-grade) or anaplastic (high-grade). In low-grade astroblastoma, treatment of choice is complete excision. This type of tumor usually does not recur. However, anaplastic tumors can recur despite surgery, radiation, and chemotherapy and may be problematic for clinician.
Case Report: A 7-year-old female patient presented with an acute onset of vomiting and seizure. Magnetic resonance imaging study revealed a large mass in the left parieto-occipital region. She underwent total excision of the tumor. Histopathologically, the tumor was an anaplastic astroblastoma. Her adjuvant treatment was planned to consist of radiation therapy and cisplatin-based chemotherapy. However, the tumor recurred early in the course, and she died 18 months after diagnosis.
Conclusion: High-grade astroblastomas behave like glioblastoma, as emphasized in this case report. Local control of this type of tumor seems difficult despite surgery, radiation therapy, and cisplatin-based chemotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00381-009-0885-8 | DOI Listing |
J Vet Med Sci
January 2025
Laboratory of Veterinary Pathology, Graduate School of Veterinary Sciences, Osaka Metropolitan University, Osaka, Japan.
A 6-year-old male rabbit (Oryctolagus cuniculus) showed loss of appetite, right side rotating and the left side circling. The symptoms did not improve, and the rabbit died on the 2nd day after presentation. Histological evaluation of the brain revealed a non-demarcated high cellularity area of neoplastic cells in the midbrain.
View Article and Find Full Text PDFJ Neurooncol
February 2025
Computational NeuroSurgery (CNS) Lab, Macquarie Medical School, Macquarie University, 75 Talavera Road, Sydney, NSW, 2109, Australia.
Purpose: Lower-grade gliomas typically exhibit 5-aminolevulinic acid (5-ALA)-induced fluorescence in only 20-30% of cases, a rate that can be increased by doubling the administered dose of 5-ALA. Fluorescence can depict anaplastic foci, which can be precisely sampled to avoid undergrading. We aimed to analyze whether a deep learning model could predict intraoperative fluorescence based on preoperative magnetic resonance imaging (MRI).
View Article and Find Full Text PDFSovrem Tekhnologii Med
November 2024
MD, PhD, Associate Professor, Head of the Department of Neurosurgery; Military Medical Academy named after S.M. Kirov, 6 Academician Lebedev St., Saint Petersburg, 194044, Russia.
Unlabelled: is to assess the effectiveness and safety of stereotactic photodynamic therapy (sPDT) with 5-aminolevulinic acid (5-ALA) in patients with recurrent malignant supratentorial gliomas in functionally relevant brain areas.
Materials And Methods: In a retrospective single-center study the results of sPDT with 5-ALA in 10 patients (6 of 10 were male), aged 30 to 62 years (median: 51.5 years; 95% CI: 38-59 years) with recurrent malignant brain gliomas after standard therapy who underwent surgery during the period of 2020-2023 were analyzed.
Neuropharmacology
January 2025
Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Akademicka 19, 20-033, Lublin, Poland. Electronic address:
The most aggressive tumors of human central nervous system are anaplastic astrocytoma (AA, III grade) and glioblastoma multiforme (GBM, IV grade) with an extremely bad prognosis. Their malignant character and resistance to standard therapy are correlated to the over-expression of survival pathways such as Ras/Raf/MEK/ERK and PLCγ1/PKC regulated by TrkB receptor. Therefore, the aim of this study was to investigate the engagement of those pathways in human glioma cells resistance for apoptosis induction by Temozolomide treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!